Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.

J Clin Oncol 2009 Jun 13;27(18):2938-45. Epub 2009 Apr 13.

Helios Klinikum, Campus Berlin Buch, Berlin, Germany.

Purpose: To compare preoperative intense dose-dense (IDD) chemotherapy with conventionally scheduled preoperative chemotherapy in high-risk primary breast cancer (BC).

Patients And Methods: In this randomized phase III trial a total of 668 eligible primary BC patients stratified for tumors > or = 3 cm (n = 567) or inflammatory BC (n = 101) were randomly assigned to receive concurrent preoperative epirubicin/paclitaxel every 3 weeks or dose-dense and dose-escalated sequential epirubicin followed by paclitaxel every 2 weeks. All patients received three cycles of cyclophosphamide, methotrexate, and fluorouracil chemotherapy after surgery.

Results: IDD treatment significantly improved pathologic complete response rate (18% v 10%; odds ratio [OR] 1.89; P = .008), disease-free survival (DFS; hazard ratio [HR], 0.71; P = .011), and overall survival (OS; HR, 0.83; P = .041) compared to epirubicin/paclitaxel. Patients with inflammatory BC had a particularly poor prognosis and did not appear to benefit from IDD therapy in this trial (DFS HR, 1.10; P = .739; OS HR, 1.25; P = .544). In contrast, patients with noninflammatory BC significantly benefited from IDD treatment (DFS HR, 0.65, P = .005; OS HR, 0.77, P = .013). Treatment effects in multivariate analysis were significant for noninflammatory BC (DFS HR, 0.65, P = .015; OS HR, 0.79, P = .034), but not for all patients (DFS HR, 0.76; P = .088; OS HR, 0.82; P = .059). IDD therapy was associated with significantly more nonhematologic toxicities, anemia, and thrombocytopenia, but with similar neutropenia and infection rates.

Conclusion: Our results support the efficacy and short-term safety of IDD as preoperative chemotherapy. IDD was less well tolerated compared to standard treatment, but improved clinical outcomes in patients with noninflammatory high-risk primary BC.

Download full-text PDF

Source
http://jco.ascopubs.org/content/27/18/2938.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.20.3133
Publisher Site
http://dx.doi.org/10.1200/JCO.2008.20.3133DOI Listing
June 2009
30 Reads

Publication Analysis

Top Keywords

preoperative chemotherapy
12
high-risk primary
12
scheduled preoperative
8
idd therapy
8
chemotherapy high-risk
8
conventionally scheduled
8
breast cancer
8
primary breast
8
treatment improved
8
idd treatment
8
patients noninflammatory
8
dfs 065
8
idd
7
patients
6
preoperative
5
dfs
5
chemotherapy
5
appear benefit
4
poor prognosis
4
prognosis appear
4

Altmetric Statistics

Similar Publications